拜耳与Souffle Therapeutics达成战略合作 共同推进细胞特异性心脏靶向siRNA疗法

投资观察
Jan 08

1月8日,拜耳公司与Souffle Therapeutics宣布达成战略合作,双方将共同推进细胞特异性心脏靶向siRNA疗法的研发。此次合作重点聚焦于开发针对特定类型扩张型心肌病的潜在最佳siRNA疗法,旨在打造同类最优治疗方案。

目前,双方尚未披露此次合作的具体财务细节。该合作将结合拜耳在心血管领域的专业优势与Souffle Therapeutics在siRNA技术平台的创新实力,共同探索心脏靶向治疗的新突破。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10